Details of Drug Off-Target (DOT)
General Information of Drug Off-Target (DOT) (ID: OTO7QW6Y)
| DOT Name | Cerebellin-4 (CBLN4) | ||||
|---|---|---|---|---|---|
| Synonyms | Cerebellin-like glycoprotein 1 | ||||
| Gene Name | CBLN4 | ||||
| Related Disease | |||||
| UniProt ID | |||||
| 3D Structure | |||||
| Pfam ID | |||||
| Sequence | 
                                         
                            MGSGRRALSAVPAVLLVLTLPGLPVWAQNDTEPIVLEGKCLVVCDSNPATDSKGSSSSPL 
                        
                    GISVRAANSKVAFSAVRSTNHEPSEMSNKTRIIYFDQILVNVGNFFTLESVFVAPRKGIY SFSFHVIKVYQSQTIQVNLMLNGKPVISAFAGDKDVTREAATNGVLLYLDKEDKVYLKLE KGNLVGGWQYSTFSGFLVFPL  | 
            ||||
| Function | 
                                         
                        Acts as a synaptic organizer in specific subsets of neurons in the brain. Essential for the formation and maintenance of inhibitory GABAergic synapses. Promotes the development of dendrite-targeting inhibitory GABAergic synapses made by somatostatin-positive interneurons. May contribute to the function of ventral medial habenula region of the brain implicated in the regulation of anxiety-related behaviors. May play a role in CBLN3 export from the endoplasmic reticulum and secretion.
                        
                     
                                     | 
            ||||
Molecular Interaction Atlas (MIA) of This DOT
| 
                     5 Disease(s) Related to This DOT 
                                                
  | 
            ||||||||||||||||||||||||||||||||||||||||||||||
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 
                     1 Drug(s) Affected the Gene/Protein Processing of This DOT 
                                                
  | 
            ||||||||||||||||||||||||||||||||||||||||||||||
| 
                     1 Drug(s) Affected the Post-Translational Modifications of This DOT 
                                                
  | 
            ||||||||||||||||||||||||||||||||||||||||||||||
References
